Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124287 | 0.90 | TACR1 (0.82) | TACR1TACR3 | |
| SCHEMBL4125582 | 0.90 | TACR1 (0.82) | TACR1CYP3A4TACR3 | |
| SCHEMBL4130115 | 0.90 | TACR1 (0.82) | TACR1CYP3A4TACR3 | |
| SCHEMBL2142457 | 0.87 | TACR1 (1.00) | TACR1CYP3A4TACR3 | |
| Netupitant SCHEMBL29809811 | 0.81 | TACR1 (1.00) | TACR1CYP3A4TACR3 | |
| Netupitant SCHEMBL445804 | 0.81 | TACR1 (1.00) | TACR1CYP3A4TACR3 | |
| Netupitant SCHEMBL30800106 | 0.81 | TACR1 (0.98) | TACR1CYP3A4TACR3 | |
| Netupitant SCHEMBL6637560 | 0.81 | TACR1 (0.98) | TACR1CYP3A4TACR3 | |
| Netupitant SCHEMBL17222804 | 0.81 | TACR1 (0.98) | TACR1CYP3A4TACR3 | |
| SCHEMBL5802858 | 0.80 | TACR1 (0.73) | TACR1CYP3A4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | claimed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | claimed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | claimed |
| EP-1187814-B1 | 5-PHENYL-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | claimed |
| US-6756380-B1 | NEUROKININ 1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | claimed |
| EP-1187814-A2 | 5-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-20 | — | — | EP | claimed |
| WO-2000073278-A2 | 5-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-07 | — | — | WO | claimed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| EP-1187814-B1 | 5-PHENYL-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| US-6756380-B1 | NEUROKININ 1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1187814-A2 | 5-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000073278-A2 | 5-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | TACR1 1/4885CYP3A4 2669/4885TACR3 43/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885CYP3A4 3086/4885TACR3 50/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885CYP3A4 3086/4885TACR3 50/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | TACR1 1/4885CYP3A4 2669/4885TACR3 43/4885 |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | TACR1 1/4885CYP3A4 3086/4885TACR3 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.